Results 1 to 10 of about 30,874 (221)
Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience [PDF]
Annals of HematologyEmicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Malcolm Su +3 more
doaj +2 more sources
Hemophilia in pediatric age [PDF]
Romanian Journal of Pediatrics, 2023 Hemophilia represents the most common inherited bleeding disorder linked to the X chromosome, which, if not properly treated, can lead to lifelong disabilities.
Cristina Elena Singer +7 more
doaj +1 more source
HEMATURIA IN HEMOPHILIA: WHAT DO WE KNOW? A CHALLENGING CASE STUDY AND LITERATURE REVIEW [PDF]
Euromediterranean Biomedical Journal, 2022 Hemophilia is a genetically determined bleeding disorder, which, if not properly managed, can cause lifelong disabilities. Hemorrhages in the joints and soft tissues are largely studied.
Alessandra Di Nora
doaj +1 more source
Clinical Pediatric Hematology-Oncology, 2022 Background : : Hemophilia requires a lifetime care for bleeding control and complications. Although patients diagnosed with hemophilia receive factor replacement, they also experience a variety of medical problems as they age.
Hyeun Su Seo +4 more
doaj +1 more source
Emicizumab-induced photosensitivity
TH Open, 2022 Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression.
Pedro Asensi Cantó +6 more
doaj +1 more source
Journal of Thrombosis and Haemostasis, 2010 Mild hemophilia A (HA), defined by clinical features and factor VIII coagulant activity (FVIII:C) between 0.05 and 0.40 IU mL(-1), is characteristically distinct from severe HA. Indeed, although the molecular characterization of mild HA has permitted the identification of specific underlying mutations, its clinical phenotype is strikingly different ...
Franchini M +2 more
openaire +2 more sources
Updates on Novel Non-Replacement Drugs for Hemophilia
Pharmaceuticals, 2022 Over the last decade, the world of hemophilia has experienced an unprecedented therapeutic advance, thanks to the progress in bioengineering technologies, leading to the introduction of drugs with novel mechanisms of action based on restoring thrombin ...
Roberta Gualtierotti +8 more
doaj +1 more source
Baylor University Medical Center Proceedings, 2019 Acquired inhibitors of coagulation are a group of rare but potentially life-threatening blood disorders characterized by the presence of autoantibodies directed against clotting factor. Autoantibody against factor VIII is the most common form of clotting factor inhibitor, a condition also known as acquired hemophilia A.
Yadav, Pandey +4 more
openaire +2 more sources
Research and Practice in Thrombosis and Haemostasis, 2021 Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products.
Beth Boulden Warren +9 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2022 Background N8‐GP (turoctocog alfa pegol; Esperoct) is a glycoPEGylated human recombinant factor VIII (FVIII). Objectives Pathfinder8 (NCT01480180) was a phase 3, multinational, open‐label, nonrandomized trial to investigate the long‐term safety and ...
Steven R. Lentz +8 more
doaj +1 more source